FDA approves new macular degeneration treatment

Share this article:

The Food and Drug Administration has approved a new drug for the treatment of the wet form of age-related macular degeneration, called Eylea. Macular degeneration is the leading cause of severe vision loss in the elderly.

Eylea, which is manufactured by Regeneron Pharmaceuticals, is a slightly less expensive treatment, costing $1,850 per injection, versus $1,950 for Genentech's Lucentis.

Both Lucentis and Eylea are still more expensive than the cancer drug Avastin, also made by Genentech. Avastin, which was recently pulled by the FDA as a breast cancer treatment option, is used as an off-label drug to treat macular degeneration, and accounts for over half of that market, The New York Times reports. Avastin costs only $50 per dose, but has been hampered recently due to reports that tainted vials of the drug infected users with Streptococcus endophthalmitis.

 

Share this article:

More in News

White House creates new national strategy on antibiotics

White House creates new national strategy on antibiotics

The Obama administration has unveiled a national strategy to combat antibiotic-resistant bacteria. It includes an executive order to direct the federal government to "reduce the emergence and spread of antibiotic-resistant ...

Medicaid provider agreement remains legitimate during bankruptcy proceedings, judge rules

Medicaid must continue to make payments to a Florida nursing home undergoing bankruptcy proceedings, a federal judge rule recently.

Legislator pushes for more HCBS services for Medicaid beneficiaries

Medicaid beneficiaries would have an opportunity to receive more care in a home or community-based setting if a House of Representatives bill passes.